Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study

Elizabeth A. Hahn*, G. Alastair Glendenning, Mark V. Sorensen, Stacie A. Hudgens, Brian J. Druker, Francois Guilhot, Richard A. Larson, Stephen G. O'Brien, Deborah G. Dobrez, Martee L. Hensley, David Cella

*Corresponding author for this work

Research output: Contribution to journalArticle

146 Scopus citations

Fingerprint Dive into the research topics of 'Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study'. Together they form a unique fingerprint.

Medicine & Life Sciences